Literature DB >> 1951638

The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat.

E Meinl1, W E Klinkert, H Wekerle.   

Abstract

In human myasthenia gravis (MG) formation of autoantibodies against acetylcholine receptor (AChR) is commonly associated with thymic changes termed lymphofollicular hyperplasia (LFH). To learn whether the thymic lesions of human MG are primary changes in the autoimmune pathogenesis, or rather secondary events caused by peripheral autoimmunization, the authors compared the pathologic changes of MG thymuses with the thymuses of Lewis rats with experimental autoimmune myasthenia gravis (EAMG). EAMG was induced either actively by immunization with AChR, or transferred passively with monoclonal antibodies (mAb) binding to AChR. The clinical diagnosis of EAMG was confirmed by electromyography. Germinal centers, which are typical for human MG thymuses, were not detectable in the thymus of EAMG rats. Scattered B cells were seen as normal components of the thymic medulla. In EAMG their number was not augmented, nor were they accumulated focally. The perivascular spaces (PVS) were not distended and the amount of reticulin was not increased. Thymic myoid cells were identified in EAMG as well as in control thymuses; their cellular microenvironment was inconspicuous. Both in normal and in EAMG thymuses, a subpopulation of myoid cells expressed the main immunogenic region of the AChR. Heavily affected rats showed a severe cortical involution, but no specific changes of the medulla. The fact that none of the thymic lesions characteristic for human MG was found in EAMG is compatible with the concept that the thymic changes in MG are primary events in the autoimmune pathogenesis of this disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1951638      PMCID: PMC1886343     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  39 in total

1.  Specific activation of lymphocytes against acetylcholine receptor in the thymus in myasthenia gravis.

Authors:  Y Fujii; J Hashimoto; Y Monden; T Ito; K Nakahara; Y Kawashima
Journal:  J Immunol       Date:  1986-02-01       Impact factor: 5.422

2.  Selective recognition of rat follicular dendritic cells (dendritic reticulum cells) by a new monoclonal antibody Ki-M4R in vitro and in vivo.

Authors:  H H Wacker; H J Radzun; V Mielke; M R Parwaresch
Journal:  J Leukoc Biol       Date:  1987-01       Impact factor: 4.962

Review 3.  The thymus in myasthenia gravis.

Authors:  H Wekerle; H K Müller-Hermelink
Journal:  Curr Top Pathol       Date:  1986

4.  Thymic extracellular matrix in myasthenia gravis.

Authors:  W Savino; S Berrih
Journal:  Lancet       Date:  1984-07-07       Impact factor: 79.321

5.  Immunohistochemical and enzyme histochemical contributions to the problem concerning the role of the thymus in the pathogenesis of myasthenia gravis.

Authors:  G Palestro; G Tridente; F Botto Micca; D Novero; G Valente; L Godio
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1983

6.  The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3.

Authors:  C D Dijkstra; E A Döpp; P Joling; G Kraal
Journal:  Immunology       Date:  1985-03       Impact factor: 7.397

7.  Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor.

Authors:  S Tzartos; S Hochschwender; P Vasquez; J Lindstrom
Journal:  J Neuroimmunol       Date:  1987-06       Impact factor: 3.478

8.  Characteristics of monoclonal antibodies to denatured Torpedo and to native calf acetylcholine receptors: species, subunit and region specificity.

Authors:  S Tzartos; L Langeberg; S Hochschwender; L W Swanson; J Lindstrom
Journal:  J Neuroimmunol       Date:  1986-01       Impact factor: 3.478

9.  Immunohistological patterns of non-neoplastic changes in the thymus in Myasthenia gravis.

Authors:  T Kirchner; B Schalke; A Melms; T von Kügelgen; H K Müller-Hermelink
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1986

10.  Thymic cytotoxic T lymphocytes are primed in vivo to minor histocompatibility antigens.

Authors:  P J Fink; M J Bevan; I L Weissman
Journal:  J Exp Med       Date:  1984-02-01       Impact factor: 14.307

View more
  12 in total

1.  Preconditioned mesenchymal stem cells treat myasthenia gravis in a humanized preclinical model.

Authors:  Muriel Sudres; Marie Maurer; Marieke Robinet; Jacky Bismuth; Frédérique Truffault; Diane Girard; Nadine Dragin; Mohamed Attia; Elie Fadel; Nicola Santelmo; Camille Sicsic; Talma Brenner; Sonia Berrih-Aknin
Journal:  JCI Insight       Date:  2017-04-06

2.  Influence of human myasthenia gravis thymus on the differentiation of human cord blood stem cells in SCID mice.

Authors:  Qian Ru Li; Ping Ping Liu; Xiao Yan Xuan; Sha Sha Guan; Ying Du; Feng Gao; Qing Yong Zhang
Journal:  Neurol Sci       Date:  2013-06-27       Impact factor: 3.307

3.  Malignant thymoma with direct invasion into the peritoneal cavity: report of a case.

Authors:  T Fujikawa; Y Nakamura; S Matsusue; H Takeda; Y Kori; M Sonobe
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

Review 4.  Vaccines against myasthenia gravis.

Authors:  Sonia Berrih-Aknin; Sara Fuchs; Miriam C Souroujon
Journal:  Expert Opin Biol Ther       Date:  2005-07       Impact factor: 4.388

Review 5.  Review on Toll-Like Receptor Activation in Myasthenia Gravis: Application to the Development of New Experimental Models.

Authors:  Marieke Robinet; Solène Maillard; Mélanie A Cron; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

6.  Current and emerging treatments for the management of myasthenia gravis.

Authors:  Sivakumar Sathasivam
Journal:  Ther Clin Risk Manag       Date:  2011-07-22       Impact factor: 2.423

Review 7.  Animal models of myasthenia gravis: utility and limitations.

Authors:  Renato Mantegazza; Chiara Cordiglieri; Alessandra Consonni; Fulvio Baggi
Journal:  Int J Gen Med       Date:  2016-03-04

Review 8.  Regulatory T cells in multiple sclerosis and myasthenia gravis.

Authors:  K M Danikowski; S Jayaraman; B S Prabhakar
Journal:  J Neuroinflammation       Date:  2017-06-09       Impact factor: 8.322

9.  Novel CXCL13 transgenic mouse: inflammation drives pathogenic effect of CXCL13 in experimental myasthenia gravis.

Authors:  Julia Miriam Weiss; Marieke Robinet; Revital Aricha; Perrine Cufi; Bérengère Villeret; Frida Lantner; Idit Shachar; Sara Fuchs; Miriam C Souroujon; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Oncotarget       Date:  2016-02-16

10.  Use of Toll-Like Receptor Agonists to Induce Ectopic Lymphoid Structures in Myasthenia Gravis Mouse Models.

Authors:  Marieke Robinet; Bérengère Villeret; Solène Maillard; Mélanie A Cron; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Front Immunol       Date:  2017-08-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.